Plasma Concentrations and AUC of Pegfilgrastim Have No Impact on Its Efficacy in Peripheral Blood Progenitor Cell Mobilization.
Frank Kroschinsky(University Hospital Carl Gustav Carus), Gerhard Ehninger(University Hospital Carl Gustav Carus), Markus Schaich(Rems-Murr-Klinikum), Uta Oelschlaegel(University Hospital Carl Gustav Carus), Rainer Ordemann, Claudia Rutt, Kristina Hoelig(Technische Universität Dresden), Eberhard Schleyer, Kirsten Poppe‐Thiede
Cited by 0
Related Papers
Midostaurin plus Chemotherapy for Acute Myeloid Leukemia with a <i>FLT3</i> Mutation
|New England Journal of Medicine|2017|2.2k
Retinoic Acid and Arsenic Trioxide for Acute Promyelocytic Leukemia
|New England Journal of Medicine|2013|1.6k
Addition of sorafenib versus placebo to standard therapy in patients aged 60 years or younger with newly diagnosed acute myeloid leukaemia (SORAML): a multicentre, phase 2, randomised controlled trial
|The Lancet Oncology|2015|402